You are here: Industry Insights > Market News > Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

expresspharmaMarch 12, 2021

Tag: Hikma , GSK , Egypt , Tunisia

Favorites

Hikma Pharmaceuticals and GlaxoSmithKline have ended talks over a potential buyout deal for the latter’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia, the companies said.

Hikma, which supplies generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives, had said in January it was planning to buy those assets.

Previous:Vir, GSK to seek EUA for COVID-19 antibody therapy

Next:Enveric Biosciences acquires licence for Diverse Biotech’s novel molecules

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets | Pharmasources.com

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos™ in internal and external product development and manufacturing programs.

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

Related News

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

You may like